Valeant won't rule out divesting Bausch + Lomb

9 September 2016 - Deborah Wilkes

Archived

Valeant Pharmaceuticals International is focusing on divesting non-core assets but will "never say never" to selling core assets like the Bausch + Lomb eyecare business, according to chairman and chief executive officer Joseph Papa.

Click tags below for more information on topics:

Bausch Health

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: